Oral cladribine and multiple sclerosis - efficacy and safety data update

Abstract

We can use oral to treat highly active relapsing-remmitting multiple sclerosis in the Czech Republic. Cladribine is administered in short-term courses followed by the long term efficacy period.

It is a selective immune reconstitution therapy (SIRT). Long term efficacy and safety of cladribine was demonstrated in the CLARITY, CLARITY Extension, ORACLE MS studies and has been followed in the long - term PREMIERE registry.

Keywords

• Oral
• cladribine
• multiple
• sclerosis
• efficacy
• safety
• data
• update